Year in Review: Dr. P Seo Novel RA therapy on the horizon: ⭐️ABBV-3373 ➡️ Adalimumab (ADA) + GC receptor modulator vs ADA ➡️ Phase II, 48 pts, previously failed MTX ➡️ Wk 12: better DAS28-CRP, ACR20/70 🚩71% of responders stayed in remission after switch to PBO #ACR23 @RheumNow